Oberon Fuels Hails Passing of California Assembly Bill 2663
28 sept. 2020 11h00 HE
|
Oberon Fuels
Reduces tax on dimethyl ether (DME) fuel to be consistent with other alternative fuelsRenewable DME (rDME) reduces greenhouse gas emissions between 68 and 101 percent compared to diesel, with zero...
Oberon Fuels Expands Operations Team as it Upgrades Renewable DME Fuel Plant
05 août 2020 12h00 HE
|
Oberon Fuels
Adds five full-time, living-wage positions in operations at plant in Brawley, California where the county unemployment rate is more than 25%; company seeking to fill four additional positionsExpansion...
eSolutions Introduces New DME Eligibility Platform Enhancement to Strengthen Providers’ Revenue Health and Profitability
25 févr. 2020 07h00 HE
|
eSolutions
OVERLAND PARK, Kan., Feb. 25, 2020 (GLOBE NEWSWIRE) -- eSolutions, a leading healthcare technology company, has released an enhancement to its Durable Medical Equipment (DME) Eligibility platform...
Oberon Fuels Partners with SHV Energy to Accelerate Use of Renewable DME (rDME) to Decarbonize Transportation
11 févr. 2020 08h30 HE
|
Oberon Fuels
When blended with propane, rDME enables propane to approach carbon neutralityFunding and collaboration builds on California Energy Commission $2.9 million grant to Oberon for increased production and...
Oberon Fuels Secures $2.9 Million Grant from State of California for First-Ever Production of Renewable Dimethyl Ether (rDME) in United States
13 juin 2019 09h00 HE
|
Oberon Fuels
Oberon will upgrade its pilot plant to test new feedstock and increase production12 full-time and up to 30 indirect jobs created, mostly in Imperial Valley region of California SAN DIEGO, June 13,...
Stratice Healthcare announces eOrdersPlus Integration with Brightree
16 oct. 2018 15h52 HE
|
Stratice Healthcare
eOrdersPlus™ solution enabling direct eOrdering connectivity between healthcare professionals & providers of patients’ medical equipment, supplies and service needs now bridges last mile of...
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial Results
27 juil. 2017 16h01 HE
|
KalVista Pharmaceuticals, Inc.
– Oral Plasma Kallikrein Inhibitor Portfolio for Treatment of Hereditary Angioedema Continues to Advance – – Intravitreal Diabetic Macular Edema Phase 2 On Track to Initiate in 2017 – CAMBRIDGE,...
Stratice Healthcare Partners with athenahealth’s ‘More Disruption Please’ Program to electronically connect physicians and suppliers via eOrdersPlus
27 juil. 2017 14h47 HE
|
Stratice Healthcare
CARMEL, Ind., July 27, 2017 (GLOBE NEWSWIRE) -- Stratice Healthcare, a leading healthcare IT company providing electronic ordering solutions connecting physician practice offices and hospital...
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
29 nov. 2016 07h30 HE
|
KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, Nov. 29, 2016 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
KalVista Pharmaceuticals Announces Closing of Merger with Carbylan Therapeutics
22 nov. 2016 07h30 HE
|
KalVista Pharmaceuticals Ltd
—Combined company renamed KalVista Pharmaceuticals, Inc., listed on Nasdaq with ticker “KALV” — —Continued focus on development of protease inhibitors with multiple molecules for oral treatment of...